Thermal breast imaging developer Computerized Thermal Imaging said it will be taking a new approach, redirecting its energies to its CTI Thermal Imaging Processor (TIP) and its photonic stimulator products.
The Food and Drug Administration (FDA) denied clearance for the vendor's BCS 2100 breast cancer diagnostic system three years ago. While the firm continued to pursue a reversal of the decision, the financial consequences have been difficult, according to CTI of Ogden, UT. As a result, CTI said it would concentrate its current efforts on a different market segment.
By AuntMinnie.com staff writers
December 19, 2005
Related Reading
Thermal imaging firm CTI wins appeal, August 31, 2004
Thermal firm CTI gets Canadian OK, April 27, 2004
Thermal firm CTI delisted from AMEX, moves to OTCBB, March 26, 2004
CTI class action suit dismissed, April 23, 2003
CTI trims loss, ups revenue in Q2, February 20, 2003
Copyright © 2005 AuntMinnie.com
